AbbVie Forecasts Significant Earnings Growth Amid Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
- Earnings Growth Forecast: AbbVie projects its adjusted diluted earnings per share (EPS) to range between $13.96 and $14.16 in 2026, a significant increase from $10.00 in 2025, indicating the company's ability to achieve profitability growth despite challenges from the loss of Humira's patent.
- Strong New Drug Performance: The new drugs Skyrizi and Rinvoq are performing exceptionally well, driving revenue diversification; despite the revenue loss from Humira, AbbVie continues to show robust growth momentum, enhancing investor confidence.
- Increased Dividend Returns: AbbVie offers a dividend yield of 3.3%, significantly higher than the S&P 500's 1.2%, and has tripled its quarterly payout rate over the past decade, demonstrating a strong commitment to shareholder returns.
- Market Valuation Analysis: While AbbVie has a high price-to-earnings ratio of 88, its actual trading multiple based on future earnings expectations is only 14, indicating that the company remains attractive in terms of long-term growth potential and stable dividends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
AbbVie Presents Late-Breaking Results from IMGN853-0420 Trial at SGO Annual Meeting
- Clinical Trial Progress: AbbVie showcased late-breaking results from the IMGN853-0420 trial at the 2026 Society of Gynecologic Oncology Annual Meeting, evaluating the efficacy of mirvetuximab soravtansine-gynx combined with carboplatin in 125 patients previously treated with platinum-based chemotherapy, indicating strong therapeutic responses that may offer new treatment options for recurrent ovarian cancer patients.
- Efficacy Assessment: The primary endpoint was the objective response rate (ORR) in FRα-positive patients, with results showing favorable responses in the ≥50% FRα subgroup after six cycles of combination therapy, suggesting the potential of this regimen to improve survival rates, particularly for patients with diminished responses to standard platinum-based chemotherapy.
- Innovative Treatment Regimen: The combination of mirvetuximab soravtansine-gynx and carboplatin not only demonstrated robust responses during the treatment phase, but many patients continued to respond during the monotherapy phase, providing new insights for future treatment strategies, especially in patients previously treated with PARP inhibitors.
- Future Research Directions: Investigators emphasized that integrating antibody-drug conjugates with standard chemotherapy could offer more options for FRα-expressing recurrent ovarian cancer patients, and AbbVie plans to further explore this area to meet the urgent need for new therapies among patients.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
3 Dividend Aristocrats Offering Yields to Help Fight Inflation
Economic Concerns: Investors are feeling uncertain as economic issues continue to impact portfolios, with inflation readings expected to show a rise, particularly influenced by higher oil prices.
Dividend Stocks as a Strategy: Amidst inflationary pressures, buying dividend stocks yielding over 3% is suggested as a strategic move for investors, especially those with a history of consistent payouts.
Company Performance: Companies like Amcor and Chevron are highlighted for their reliable dividend growth, with Amcor increasing payouts for 27 consecutive years and Chevron maintaining a strong position in the energy sector.
Healthcare Sector Resilience: AbbVie is noted for its reliable growth and income in healthcare, with a strong revenue performance and continued dividend increases, making it a solid investment choice amidst inflation concerns.
See More
ABBVIE AIMS TO ELIMINATE LOOPHOLES AND ENHANCE ACCOUNTABILITY IN THE 340B PROGRAM
Program Overview: The initiative focuses on closing loopholes and enhancing accountability within a specific program involving 340B.
Goals and Objectives: The primary aim is to strengthen the integrity and effectiveness of the 340B program, ensuring it serves its intended purpose.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
AbbVie Presents Late-Breaking Results from IMGN853-0420 Trial at SGO Annual Meeting
- Clinical Trial Progress: AbbVie showcased late-breaking results from the IMGN853-0420 trial at the 2026 Society of Gynecologic Oncology Annual Meeting, evaluating the efficacy of mirvetuximab soravtansine-gynx combined with carboplatin in 125 patients previously treated with platinum-based chemotherapy, indicating strong therapeutic responses that may offer new treatment options for recurrent ovarian cancer patients.
- Efficacy Assessment: The primary endpoint was the objective response rate (ORR) in FRα-positive patients, with results showing favorable responses in the ≥50% FRα subgroup after six cycles of combination therapy, suggesting the potential of this regimen to improve survival rates, particularly for patients with diminished responses to standard platinum-based chemotherapy.
- Innovative Treatment Regimen: The combination of mirvetuximab soravtansine-gynx and carboplatin not only demonstrated robust responses during the treatment phase, but many patients continued to respond during the monotherapy phase, providing new insights for future treatment strategies, especially in patients previously treated with PARP inhibitors.
- Future Research Directions: Investigators emphasized that integrating antibody-drug conjugates with standard chemotherapy could offer more options for FRα-expressing recurrent ovarian cancer patients, and AbbVie plans to further explore this area to meet the urgent need for new therapies among patients.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
3 Dividend Aristocrats Offering Yields to Help Fight Inflation
Economic Concerns: Investors are feeling uncertain as economic issues continue to impact portfolios, with inflation readings expected to show a rise, particularly influenced by higher oil prices.
Dividend Stocks as a Strategy: Amidst inflationary pressures, buying dividend stocks yielding over 3% is suggested as a strategic move for investors, especially those with a history of consistent payouts.
Company Performance: Companies like Amcor and Chevron are highlighted for their reliable dividend growth, with Amcor increasing payouts for 27 consecutive years and Chevron maintaining a strong position in the energy sector.
Healthcare Sector Resilience: AbbVie is noted for its reliable growth and income in healthcare, with a strong revenue performance and continued dividend increases, making it a solid investment choice amidst inflation concerns.
See More
ABBVIE AIMS TO ELIMINATE LOOPHOLES AND ENHANCE ACCOUNTABILITY IN THE 340B PROGRAM
Program Overview: The initiative focuses on closing loopholes and enhancing accountability within a specific program involving 340B.
Goals and Objectives: The primary aim is to strengthen the integrity and effectiveness of the 340B program, ensuring it serves its intended purpose.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
